$1.60
-0.01 (-0.62%)
Open$1.62
Previous Close$1.61
Day High$1.63
Day Low$1.57
52W High$19.40
52W Low$1.31
Volume—
Avg Volume1.57M
Market Cap61.00M
P/E Ratio—
EPS$-1.47
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
+1,983.1% upside
Current
$1.60
$1.60
Target
$33.33
$33.33
$30.09
$33.33 avg
$42.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.99M | 20.76M | 15.61M |
| Net Income | 4.98M | 4.98M | 3.68M |
| Profit Margin | 24.9% | 24.0% | 23.6% |
| EBITDA | 7.23M | 8.32M | 5.37M |
| Free Cash Flow | 5.95M | 3.82M | 3.47M |
| Rev Growth | +24.3% | +21.0% | +20.1% |
| Debt/Equity | 0.81 | 0.72 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |